Subsidy refused: hep C patients to pay their way

The government last year changed its practice of automatically listing new products deemed safe, effective and cost-effective by the TGA’s Pharmaceutical Benefits Advisory Committee (PBAC), saying the drugs must be approved by Cabinet before they could be listed.

It later bowed to pressure from industry and consumer groups, agreeing to automatically allow PBAC-approved products onto the PBS if they were likely to cost under $10 million a year.

It recently